Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ASSEMBLY BIOSCIENCES, INC. (ASMB)

Assembly Biosciences Q2 net loss narrows to $3.9 million from $10.2 million

Positive Impact 3 of 5 earnings Written later

Assembly Biosciences reported second quarter 2026 results, with collaboration revenue from Gilead rising to $13.4 million from $9.6 million and net loss falling to $3.9 million, or $0.20 per share, from $10.2 million, or $1.33 per share. The company completed $115 million in gross financing and said its cash position is projected to fund operations into 2029, which supports its pipeline programs.

Key points

  • Collaboration revenue was $13.4 million for the quarter ended June 30, 2026, compared with $9.6 million a year earlier, including a $5.1 million cumulative catch-up adjustment.
  • Net loss attributable to common stockholders was $3.9 million, or $0.20 per share, versus $10.2 million, or $1.33 per share, in the same period of 2025.
  • Cash, cash equivalents and marketable securities were $320.4 million at June 30, 2026, up from $226.6 million at March 31, 2026.
  • Completed $115 million gross financing; GS-1179 is expected to start a Phase 2 trial by year-end 2026.

The filing

CompanyASSEMBLY BIOSCIENCES, INC. (ASMB)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:11 PM ET
Accession number0001193125-26-349198

Items reported: 2.01 Acquisition or Disposition Completed

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.